[
  {
    "ts": null,
    "headline": "Nonprofit Health Services Organization Files Lawsuit Against Fortune 500 Pharmaceutical Company Over Prescription Drug Access",
    "summary": "LAS VEGAS, January 20, 2026--Sagebrush Health Services, a nonprofit organization serving over 10,000 Nevada patients, has filed a lawsuit against Amgen Inc. (NASDAQ: AMGN), alleging that Amgen acted unlawfully by unilaterally terminating the sale of discounted drugs to Sagebrush’s clinics and improperly retracting millions of dollars in past discounts. These actions, Sagebrush maintains, temporarily prevented it from supplying its clinics with necessary medications from Amgen and other manufactu",
    "url": "https://finnhub.io/api/news?id=ba211069ff8d101426aeda216c511b92d4cfa61f139a9fbd50d2592ed2f3ea78",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768926840,
      "headline": "Nonprofit Health Services Organization Files Lawsuit Against Fortune 500 Pharmaceutical Company Over Prescription Drug Access",
      "id": 138188543,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "LAS VEGAS, January 20, 2026--Sagebrush Health Services, a nonprofit organization serving over 10,000 Nevada patients, has filed a lawsuit against Amgen Inc. (NASDAQ: AMGN), alleging that Amgen acted unlawfully by unilaterally terminating the sale of discounted drugs to Sagebrush’s clinics and improperly retracting millions of dollars in past discounts. These actions, Sagebrush maintains, temporarily prevented it from supplying its clinics with necessary medications from Amgen and other manufactu",
      "url": "https://finnhub.io/api/news?id=ba211069ff8d101426aeda216c511b92d4cfa61f139a9fbd50d2592ed2f3ea78"
    }
  },
  {
    "ts": null,
    "headline": "CURE: Benefits And Caveats Of The Leveraged Healthcare ETF",
    "summary": "Direxion CURE ETF offers 3x daily healthcare exposureâlearn risks like volatility decay and drift, plus tactical trading tips using XLV/index signals.",
    "url": "https://finnhub.io/api/news?id=ca3612c5b4891b901620bb4fdb6c38f001242d9ac0824dccbf1890b2577a24b9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768912790,
      "headline": "CURE: Benefits And Caveats Of The Leveraged Healthcare ETF",
      "id": 138188296,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1351287260/image_1351287260.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "Direxion CURE ETF offers 3x daily healthcare exposureâlearn risks like volatility decay and drift, plus tactical trading tips using XLV/index signals.",
      "url": "https://finnhub.io/api/news?id=ca3612c5b4891b901620bb4fdb6c38f001242d9ac0824dccbf1890b2577a24b9"
    }
  },
  {
    "ts": null,
    "headline": "A Look At Amgen (AMGN) Valuation After Strong Q3 Results And Pipeline Momentum",
    "summary": "Why Amgen’s recent move is tied to earnings and pipeline news Amgen (AMGN) has been back on many investors’ screens after a strong third quarter, with double digit revenue growth and a wider mix of drugs contributing to sales, alongside several upcoming product and trial milestones. The stock has also climbed about 11.7% over the past 3 months as part of the Zacks Earnings Certain Admiral Portfolio, drawing attention from investors who focus on long term earnings consistency and defense in...",
    "url": "https://finnhub.io/api/news?id=93db169096650666e11cb8c6c5599de7650f62fb5a57714060fddb76e93a2bc1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768871227,
      "headline": "A Look At Amgen (AMGN) Valuation After Strong Q3 Results And Pipeline Momentum",
      "id": 138181950,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Why Amgen’s recent move is tied to earnings and pipeline news Amgen (AMGN) has been back on many investors’ screens after a strong third quarter, with double digit revenue growth and a wider mix of drugs contributing to sales, alongside several upcoming product and trial milestones. The stock has also climbed about 11.7% over the past 3 months as part of the Zacks Earnings Certain Admiral Portfolio, drawing attention from investors who focus on long term earnings consistency and defense in...",
      "url": "https://finnhub.io/api/news?id=93db169096650666e11cb8c6c5599de7650f62fb5a57714060fddb76e93a2bc1"
    }
  }
]